Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

February 2015

Granix Now Covered Under Pharmacy Benefit 


The FDA recently approved Granix for self-administration, and Harvard Pilgrim will now cover it under the pharmacy benefit on the following tiers:

  • Tier 3 on the 3-Tier Premium Formulary
  • Tier 4 on the 4-Tier Premium Formulary
  • Tier 3 on the 4-Tier Value Formulary
  • Tier 4 on the 5-Tier Value Formulary 

Granix (tbo-filgrastim) is a leukocyte growth factor prescribed to people with nonmyeloid malignancies who are receiving chemotherapy that affects the bone marrow to decrease the length of time that certain white blood cells (neutrophils) are very low (severe neutropenia).

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

Reminder: CAQH Switching to New Version February 24-March 2

Data Sharing Enhancements

CLINICIAN CORNER

Coverage of New Hepatitis C Medication Harvoni

Fentanyl Patch and Xartemis XR Quantity Limit

Granix Now Covered Under Pharmacy Benefit

Prior Authorization Required for Afrezza

Prior Authorization Required for Otezla

Tier Increase for Rebif on Premium Formularies

Caring for a Caregiver: Signs and Treatment of Caregiver Stress

OFFICE ASSISTANT

Update to CPT and HCPCS Level II Modifiers Payment Policy

Urgent Care Network Requirements

PUBLICATION INFORMATION

Eric H. Schultz,
President and Chief Executive Officer

Richard Weisblatt PhD,
Senior Vice President, Provider Network

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator